Cargando…

PB2062: EPIDEMIOLOGICAL, CLINICAL AND THERAPEUTIC FEATURES OF REFRACTORY HODGKIN’S LYMPHOMA.

Detalles Bibliográficos
Autores principales:	Ben Sghaier, R., kmira, Z., bouslama, E., zaier, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431398/ http://dx.doi.org/10.1097/01.HS9.0000851080.24323.d4

Ejemplares similares

PB2263: TOXICITY PROFILE OF SALVAGE CHEMOTHERAPY REGIMENS IN PATIENTS WITH RELAPSED/ REFRACTORY HODGKIN LYMPHOMA.
por: Zahra, Kmira, et al.
Publicado: (2023)

PB2262: PROGNOSTIC FACTORS IN PATIENTS WITH RELAPSED/REFRACTORY HODGKINN LYMPHOMA
por: Zahra, Kmira, et al.
Publicado: (2023)

PB2556: MEGALOBLASTIC ANEMIA: EPIDEMIOLOGICAL, CLINICAL, AND ETIOLOGICAL PROFILE: ABOUT 200 CASES.
por: Zahra, Kmira, et al.
Publicado: (2023)

PB2064: RELAPSED/REFRACTORY HODGKIN LYMPHOMA PATIENTS TREATED WITH RADIOTHERAPY
por: Kallel, F., et al.
Publicado: (2022)

PB2063: CHARACTERISTICS AND THERAPEUTIC RESULTS OF PATIENTS WITH REFRACTORY/RELAPSED HODGKIN LYMPHOMA IN A TUNISIAN CENTER
por: Kammoun, F., et al.
Publicado: (2022)

PB1739: ADVERSE EFFECTS OF ASPARAGINASE IN THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA
por: Chenbah, Wafa, et al.
Publicado: (2023)

PB2435: ALLOGENEIC STEM CELL TRANSPLANTATION OUTCOMES IN HODGKIN LYMPHOMA: A PROGNOSTIC STUDY OF 30 PATIENTS WITH RELAPSED AND REFRACTORY HODGKIN LYMPHOMA
por: Zamani, Shayan, et al.
Publicado: (2023)

PB2256: EPIDEMIOLOGY AND OUTCOMES OF HODGKIN LYMPHOMA IN URUGUAY. A NATIONAL REGISTRY
por: Oliver, Carolina, et al.
Publicado: (2023)

PB2062: PAROXYSMAL NOCTURNAL HEMOGLOBINURIA SCREENING AFTER INTRODUCTION OF HIGH-SENSITIVITY DIAGNOSTICS – A SINGLE-CENTER 10-YEAR EXPERIENCE
por: Głodkowska-Mrówka, Eliza, et al.
Publicado: (2023)

PB2254: TREATMENT OUTCOME AND PROGNOSTIC FACTORS IN CHILDREN AND ADOLESCENTS WITH RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA
por: Ali, Nesreen, et al.
Publicado: (2023)

PB2241: CHARACTERISTICS AND OUTCOME OF WARM AUTOIMMUNE HEMOLYTIC ANEMIA (WAIHA) IN ADULTS: A RETROSPECTIVE ANALYSIS OF 110 TUNISIAN PATIENTS
por: Bouslama, E., et al.
Publicado: (2022)

PB2259: THE NEW PD-1 INHIBITOR PROLGOLIMAB IN THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN’S LYMPHOMA
por: Semenova, Anastasia, et al.
Publicado: (2023)

PB2284: EPIDEMIOLOGICAL, CLINICAL AND THERAPEUTIC ASPECT OF INDOLENT LYMPHOMAS IN TUNISIA
por: Charef, Ons, et al.
Publicado: (2023)

PB2369: PERIPHERAL T CELL LYMPHOMA: EPIDEMIOLOGY AND CLINICAL CHARACTERISTICS
por: Charfi, Maha, et al.
Publicado: (2023)

PB2282: HERPESVIRUSES REPLICATION DURING COVID-19 IN NON-HODGKIN’S LYMPHOMA PATIENTS.
por: Sychevskaya, K., et al.
Publicado: (2022)

PB2324: USE OF COMBINATION OF THALIDOMIDE, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN PATIENTS WITH REFRACTORY/RELAPSED NON-HODGKIN LYMPHOMA: A PALLIATIVE CHEMOTHERAPY STRATEGY.
por: Martinez, Celia, et al.
Publicado: (2023)

PB2155: B-CELL NON-HODGKIN’S LYMPHOMAS ASSOCIATED WITH AMYLOIDOSIS
por: Navrátilova, M., et al.
Publicado: (2022)

PB2402: CLINICAL CHARACTERISTICSAND PROGNOSIS RISK FACTORS OF NON-HODGKIN’S LYMPHOMA INVOLVING THE HEART
por: Chen, Yue, et al.
Publicado: (2023)

PB2320: FIRST LINE THERAPY FOR DIFFUSE LARGE B CELL LYMPHOMA AMONG THE ELDERLY: A TUNISIAN MULTICENTER EXPERIENCE.
por: Zahra, Kmira, et al.
Publicado: (2023)

PB2383: MICROSATELLITE INSTABILITY AND 9P24.1 ALTERATIONS IN HODGKIN LYMPHOMA
por: Tregubova, Ekaterina, et al.
Publicado: (2023)

PB2321: THE EFFECT OF PRE-TREATMENT SERUM KINDLIN-3 ON HODGKIN AND NON-HODGKIN LYMPHOMAS: A SINGLE CENTER EXPERIENCE
por: Keskin, Melike, et al.
Publicado: (2023)

PB2436: EFFICACY AND SAFETY PROFILE OF EVEROLIMUS AS A MAINTENANCE THERAPY FOR PRIMARY REFRACTORY/RELAPSING HODGKIN LYMPHOMA FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Zamani, Shayan, et al.
Publicado: (2023)

PB2255: ASSESSMENT OF CHEMOTHERAPY-INDUCED TOXICITY IN CHILDREN WITH HODGKIN LYMPHOMA RECEIVING THE EURONET PROTOCOL
por: Bekhit, Hala, et al.
Publicado: (2023)

PB2366: TRIAL IN PROGRESS: PHASE 1 TRIAL EVALUATING THE SAFETY AND TOLERABILITY OF ODRONEXTAMAB IN COMBINATION WITH CEMIPLIMAB IN RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA
por: Segura, Cecilia Carmen Carpio, et al.
Publicado: (2023)

PB2340: FIRST LINE THERAPY FOR DIFFUSE LARGE B CELL LYMPHOMA AMONGPATIENTS AGED LESS THAN 60 YEARS: A TUNISIAN MULTICENTER EXPERIENCE.
por: Zahra, Kmira, et al.
Publicado: (2023)

PB1982: EPIDEMIOLOGICAL, CLINICAL AND THERAPEUTIC FEATURES OF CHRONIC MYELOID LEUKEMIA: EXPERIENCE OF FATTOUMA BOURGUIBA HOSPITAL OF MONASTIR
por: Lakhel, Sana, et al.
Publicado: (2023)

PB2065: IMPORTANCE OF PET AS A PROGNOSTIC MARKER IN TREATMENT STRATEGY CHOICE IN PATIENTS WITH HODGKIN LYMPHOMA
por: Novosad, O., et al.
Publicado: (2022)

PB2257: OUTCOME AND PROGNOSTIC FACTORS OF PEDIATRIC PATIENTS WITH HODGKIN LYMPHOMA: A SINGLE-CENTER EXPERIENCE
por: Ali, Nesreen, et al.
Publicado: (2023)

PB2316: SAFETY AND EFFICACY OF AUTOLOGOUS HSCT IN NINE PATIENTS WITH AIDS-RELATED NON-HODGKIN LYMPHOMA
por: Liu, Jun, et al.
Publicado: (2023)

PB1919: MATURE B-CELL NEOPLASMS CD5 NEGATIVE: CONFRONTATION CYTOMETRY-CYTOLOGY
por: Cheikh, Hanen Ben, et al.
Publicado: (2023)

PB2156: ANALYSIS OF POSSIBLE CLONAL ORIGIN OF LARGE B-CELL DIFFUSED LYMPHOMAS ARISING IN PATIENTS WITH PRE-EXISTING HODGKIN’S LYMPHOMA
por: Masciopinto, P., et al.
Publicado: (2022)

PB2072: EFFICACY AND SIDE EFFECTS OF IBRUTINIB IN RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA
por: Basturk, A., et al.
Publicado: (2022)

PB2100: MANAGEMENT OF RELAPSED / REFRACTORY (R/R) B-CELL NON HODGKIN LYMPHOMA (B-NHL) WITH ANTI-CD20XCD3 BISPECIFIC ANTIBODY GLOFITAMAB. A SINGLE CENTER EXPERIENCE.
por: Giatra, C., et al.
Publicado: (2022)

PB2066: THE STUDY OF GSTP1 AND MDR1 GENES POLYMORPHISMS IN HODGKIN’S LYMPHOMA AND THEIR LINK WITH CHEMOTHERAPY RESPONSE.
por: Voytko, M., et al.
Publicado: (2022)

PB2322: MULTIPLE PRIMARY TUMORS IN PATIENTS WITH NON-HODGKIN’S LYMPHOMA: A RETROSPECTIVE SINGLE-CENTER STUDY
por: Sahakyan, Lusine, et al.
Publicado: (2023)

PB2415: THE ROLE OF NUTRITIONAL SUPPORT DURING AUTOLOGOUS STEM CELL TRANSPLANTATION (AUTOHSCT) IN PATIENTS WITH HODGKIN LYMPHOMA.
por: Volchenkov, Stanislav, et al.
Publicado: (2023)

PB2260: FIVE-YEAR SINGLE-CENTER EXPERIENCE IN THE TREATMENT OF ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA WITH ABVD
por: Vukovic, Vojin, et al.
Publicado: (2023)

PB2069: ELTROMBOPAG WITH IMMUNO SUPPRESSIVE THERAPY IN SEVERE ACQUIRED APLASTIC ANEMIA IN CHILDREN AND ADOLESCENTS: A MONOCENTRIC EXPERIENCE
por: Sayed, Nesrine Ben, et al.
Publicado: (2023)

PB2160: ASSOCIATION OF BCL-2 EXPRESSING TUMOR CELLS WITH RESPONSE TO FRONTLINE CHEMOTHERAPY IN NODULAR SCLEROSIS HODGKIN LYMPHOMA
por: Diakonov, D., et al.
Publicado: (2022)

PB2277: PROGNOSTIC SIGNIFICANCE OF SERUM MONOCLONAL PROTEINS BASED ON IMMUNOFIXATION ELECTROPHORESIS IN B CELL NON-HODGKIN LYMPHOMA
por: Gao, Yuyang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_b6ekoortbjcshkn7fj8mls2b86